Page 169«..1020..168169170171..180190..»

Genetic and Genomic Medicine – Nationwide Children’s Hospital

Posted: October 13, 2022 at 2:26 am

Services We Offer

Services we offer include:

Learn More About Our Services

A genetics consult starts with a phone call from a genetic counseling assistant. The assistant will gather information about the reason for the visit, obtain a detailed history of any problems in the family (which is called a pedigree) and possibly request medical records from other providers or hospitals. Sometimes, the assistant may need sensitive information. During this first contact, if you do not want to come for a full visit or have concerns about sharing sensitive information, please let us know.

The first appointment will take about two hours.If the person who is referred is a child, they MUST come to the visit. Plan to arrive at least 30 minutes before your appointment time to allow ample time to get registered, complete forms and have measurements taken (height, weight, blood pressure).

You will meet with several healthcare providers at this visit. This will include a genetic counselor, a genetic nurse practitioner or genetics physician, and possibly a metabolic dietician.

A consult with genetics is more than having genetic testing. It includes a full assessment that consists of taking a detailed history, reviewing outside medical records and performing a complete exam. We will discuss possible conditions, provide genetic counseling and review what may be needed to establish a diagnosis. A decision about whether testing is required, and what kind of tests should be performed, will be discussed at the first visit.

In most cases, testing will not be done at that time. If testing is recommended, we will work with your insurance to get prior authorization and let you know when to return for testing.

A return visit with the nurse practitioner, geneticist or genetic counselor is often needed when test results are available. Our team will go over what the results mean and discuss any next steps. Genetic counseling will be provided at every step to ensure you understand what the results mean for the patient and the family. Finally, any needed additional tests will be ordered, and a care plan with specific treatments, if available, will be made.

Clinical services are supported partly by the Ohio Department of Health as a Regional Genetics Center of the State of Ohio, Region IV.

Kim L. McBride, MD, MS, is Division Chief of Genetic and Genomic Medicine at Nationwide Children's Hospital.

Murugu Manickam, MD, MPH, FACMG, is Section Chief of Genetic and Genomic Medicine at Nationwide Children's Hospital.

Genetics ClinicTower Building, 4th Floor, Suite D700 Children's DriveColumbus, OH 43205(614) 722-3535FAX (614) 722-3546Metabolic ClinicTower Building, 4th Floor, Suite D700 Childrens DriveColumbus, OH 43205(614) 722-3543FAX (614) 722-3546Dublin Genetics ClinicDublin Medical Office Building5665 Venture DriveDublin, OH 43017(614) 722-3535FAX (614) 722-3546Tuesdays all day

Westerville Genetics ClinicClose To Home Center on N. Cleveland AvenueWesterville, OH 43082(614) 722-3535FAX (614) 722-3546Mondays 12:30 pm 5:00pm

Athens Outreach278 W. Union StreetAthens, OH 45701To schedule, call: (614) 592-4431FAX (614) 594-9929Held bimonthly on a Wednesday

Marietta OutreachMarietta City Health Department304 Putnam StreetMarietta, OH 45750To schedule, call: (740) 373-0611FAX (740) 376-2008Held bimonthly on a Wednesday

Waverly OutreachPike County General Health District14050 US23 NWaverly, Ohio 45690To schedule, call: (614) 722-3535Fax referral to: (614) 722-3546Office Phone: (740) 947-7721Office Fax (740) 947-1109Held bimonthly on a Wednesday

Zanesville OutreachMuskingham Valley Health Care719 Adair AvenueZanesville, Ohio 43701To schedule, call: (614) 722-3535Fax referral to: (614) 722-3546Held bimonthly on a Wednesday

22q CenterNationwide Childrens Hospital700 Childrens DriveColumbus, OH 43205(614) 722-6200FAX (614) 722-4000Office phone (614) 962-6373

Complex Epilepsy Clinic (Epilepsy Center)Nationwide Childrens Hospital700 Childrens DriveColumbus, OH 43205(614) 722-6200FAX (614) 722-4000

Cleft Lip and Palate CenterNationwide Childrens Hospital700 Children's DriveSuite T5EColumbus, Ohio 43205(614) 722-6200FAX (614) 722-4000Office phone (614) 962-6366Tues. 12:30 pm 5 pm

Cystic Fibrosis ClinicOutpatient Care Center, 5th Floor555 S. 18th StreetColumbus, OH 43205Phone: (614) 722-4766Fax: (614) 722-4755Tues PM, Wed PM, and Thurs PM

Down Syndrome Clinic (Developmental and Behavioral Pediatrics)Nationwide Childrens Hospital700 Childrens DriveColumbus, OH 43205(614) 722-6200FAX (614) 722-4000Office phone (614) 722-4050

Muscular Dystrophy Association(MDA)/Spinal Muscular Atrophy (SMA) ClinicOutpatient Care Center, 1st Floor555 S. 18th StreetColumbus, OH 43205(614) 722-6200FAX (614) 722-4000Office phone (614) 722-2203Wednesdays

Myelomeningocele Clinic (Developmental and Behavioral Pediatrics)Nationwide Childrens Hospital700 Childrens DriveColumbus, OH 43205(614) 722-6200FAX (614) 722-4000Office phone (614) 722-4050Friday AM

Prader-Willi Syndrome Clinic (Endocrinology)Outpatient Care Center, 5th Floor555 S. 18th StreetColumbus, OH 43205(614) 722-6200FAX (614) 722-4000Office phone (614) 722-44252nd Friday of the month

Williams Syndrome Clinic (Developmental and Behavioral Pediatrics)Nationwide Childrens Hospital700 Childrens DriveColumbus, OH 43205(614) 722-6200FAX (614) 722-4000Office phone (614) 722-40502nd Tuesday of the month

The mission of the Center for Gene Therapy is to investigate and employ the use of gene- and cell-based therapeutics for prevention and treatment of human diseases.

The Center for Cardiovascular Research conducts innovative research leading to improved therapies and outcomes for pediatric cardiovascular diseases and promotes cardiovascular health in adults.

Go here to read the rest:
Genetic and Genomic Medicine - Nationwide Children's Hospital

Posted in Genetic medicine | Comments Off on Genetic and Genomic Medicine – Nationwide Children’s Hospital

Carrier Screening for Genetic Conditions | ACOG

Posted: October 13, 2022 at 2:26 am

Number 691 (Replaces Committee Opinion Number 318, October 2005; Committee Opinion Number 432, May 2009; Committee Opinion Number 442, October 2009; Committee Opinion Number 469, October 2010; Committee Opinion Number 486, April 2011. Reaffirmed 2020)

Committee on Genetics

This Committee Opinion was developed by the American College of Obstetricians and Gynecologists Committee on Genetics in collaboration with committee members Britton Rink, MD; Stephanie Romero, MD; Joseph R. Biggio Jr, MD; Devereux N. Saller Jr, MD; and Rose Giardine, MS.

This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed.

ABSTRACT: Carrier screening is a term used to describe genetic testing that is performed on an individual who does not have any overt phenotype for a genetic disorder but may have one variant allele within a gene(s) associated with a diagnosis. Information about carrier screening should be provided to every pregnant woman. Carrier screening and counseling ideally should be performed before pregnancy because this enables couples to learn about their reproductive risk and consider the most complete range of reproductive options. A patient may decline any or all screening. When an individual is found to be a carrier for a genetic condition, his or her relatives are at risk of carrying the same mutation. The patient should be encouraged to inform his or her relatives of the risk and the availability of carrier screening. If an individual is found to be a carrier for a specific condition, the patients reproductive partner should be offered testing in order to receive informed genetic counseling about potential reproductive outcomes. If both partners are found to be carriers of a genetic condition, genetic counseling should be offered. What follows is a detailed discussion of some of the more common genetic conditions for which carrier screening is recommended in at least some segments of the population.

The American College of Obstetricians and Gynecologists (the College) makes the following recommendations and conclusions:

Information about genetic carrier screening should be provided to every pregnant woman. After counseling, a patient may decline any or all screening.

Carrier screening and counseling ideally should be performed before pregnancy.

If an individual is found to be a carrier for a specific condition, the individuals reproductive partner should be offered testing in order to receive informed genetic counseling about potential reproductive outcomes. Concurrent screening of the patient and her partner is suggested if there are time constraints for decisions about prenatal diagnostic evaluation.

If both partners are found to be carriers of a genetic condition, genetic counseling should be offered. Prenatal diagnosis and advanced reproductive technologies to decrease the risk of an affected offspring should be discussed.

When an individual is found to be a carrier for a genetic condition, the individuals relatives are at risk of carrying the same mutation. The patient should be encouraged to inform his or her relatives of the risk and the availability of carrier screening. The obstetriciangynecologist or other health care provider should not disclose this information without permission from the patient.

It is important to obtain the family history of the patient and, if possible, her partner as a screening tool for inherited risk. The family history should include the ethnic background of family members as well as any known consanguinity. Individuals with a positive family history of a genetic condition should be offered carrier screening for the specific condition and may benefit from genetic counseling.

Carrier screening for a particular condition generally should be performed only once in a persons lifetime, and the results should be documented in the patients health record. Because of the rapid evolution of genetic testing, additional mutations may be included in newer screening panels. The decision to rescreen a patient should be undertaken only with the guidance of a genetics professional who can best assess the incremental benefit of repeat testing for additional mutations.

Prenatal carrier screening does not replace newborn screening, nor does newborn screening replace the potential value of prenatal carrier screening.

If a patient requests carrier screening for a particular condition for which testing is readily available and which reasonably would be considered in another screening strategy, the requested test should be offered to her (regardless of ethnicity and family history) after counseling on the risks, benefits, and limitations of screening.

The cost of carrier screening for an individual condition may be higher than the cost of testing through commercially available expanded carrier screening panels. When selecting a carrier screening approach, the cost of each option to the patient and the health care system should be considered.

Screening for spinal muscular atrophy should be offered to all women who are considering pregnancy or are currently pregnant.

In patients with a family history of spinal muscular atrophy, molecular testing reports of the affected individual and carrier testing of the related parent should be reviewed, if possible, before testing. If the reports are not available, SMN1 deletion testing should be recommended for the low-risk partner.

Cystic fibrosis carrier screening should be offered to all women who are considering pregnancy or are currently pregnant.

Complete analysis of the CFTR gene by DNA sequencing is not appropriate for routine carrier screening.

For couples in which both partners are unaffected but one or both has a family history of cystic fibrosis, genetic counseling and medical record review should be performed to determine if CFTR mutation analysis in the affected family member is available.

If a womans reproductive partner has cystic fibrosis or apparently isolated congenital bilateral absence of the vas deferens, the couple should be provided follow-up genetic counseling by an obstetriciangynecologist or other health care provider with expertise in genetics for mutation analysis and consultation.

A complete blood count with red blood cell indices should be performed in all women who are currently pregnant to assess not only their risk of anemia but also to allow assessment for risk of a hemoglobinopathy. Ideally, this testing also should be offered to women before pregnancy.

A hemoglobin electrophoresis should be performed in addition to a complete blood count if there is suspicion of hemoglobinopathy based on ethnicity (African, Mediterranean, Middle Eastern, Southeast Asian, or West Indian descent). If red blood cell indices indicate a low mean corpuscular hemoglobin or mean corpuscular volume, hemoglobin electrophoresis also should be performed.

Fragile X premutation carrier screening is recommended for women with a family history of fragile X-related disorders or intellectual disability suggestive of fragile X syndrome and who are considering pregnancy or are currently pregnant.

If a woman has unexplained ovarian insufficiency or failure or an elevated follicle-stimulating hormone level before age 40 years, fragile X carrier screening is recommended to determine whether she has an FMR1 premutation.

All identified individuals with intermediate results and carriers of a fragile X premutation or full mutation should be provided follow-up genetic counseling to discuss the risk to their offspring of inheriting an expanded full-mutation fragile X allele and to discuss fragile X-associated disorders (premature ovarian insufficiency and fragile X tremor/ataxia syndrome).

Prenatal diagnostic testing for fragile X syndrome should be offered to known carriers of the fragile X premutation or full mutation.

DNA-based molecular analysis (eg, Southern blot analysis and polymerase chain reaction) is the preferred method of diagnosis of fragile X syndrome and of determining FMR1 triplet repeat number (eg, premutations). In rare cases, the size of the triplet repeat and the methylation status do not correlate, which makes it difficult to predict the clinical phenotype. In cases of this discordance, the patient should be referred to a genetics professional.

When only one partner is of Ashkenazi Jewish descent, that individual should be offered screening first. If it is determined that this individual is a carrier, the other partner should be offered screening. However, the couple should be informed that the carrier frequency and the detection rate in non-Jewish individuals are unknown for most of these disorders, except for TaySachs disease and cystic fibrosis. Therefore, it is difficult to accurately predict the couples risk of having a child with the disorder.

Screening for TaySachs disease should be offered when considering pregnancy or during pregnancy if either member of a couple is of Ashkenazi Jewish, FrenchCanadian, or Cajun descent. Those with a family history consistent with TaySachs disease also should be offered screening.

When one member of a couple is at high risk (ie, of Ashkenazi Jewish, FrenchCanadian, or Cajun descent or has a family history consistent with TaySachs disease) but the other partner is not, the high-risk partner should be offered screening. If the high-risk partner is found to be a carrier, the other partner also should be offered screening.

Enzyme testing in pregnant women and women taking oral contraceptives should be performed using leukocyte testing because serum testing is associated with an increased false-positive rate in these populations.

If TaySachs disease screening is performed as part of pan-ethnic expanded carrier screening, it is important to recognize the limitations of the mutations screened in detecting carriers in the general population. In the presence of a family history of TaySachs disease, expanded carrier screening panels are not the best approach to screening unless the familial mutation is included on the panel.

Referral to an obstetriciangynecologist or other health care provider with genetics expertise may be helpful in instances of inconclusive enzyme testing results or in discussion of carrier testing of an individual with non-Ashkenazi Jewish ethnicity whose reproductive partner is a known carrier of TaySachs disease.

Carrier screening is a term used to describe genetic testing that is performed on an individual who does not have any overt phenotype for a genetic disorder but may have one variant allele within a gene(s) associated with a diagnosis. Information about genetic carrier screening should be provided to every pregnant woman. After counseling, a patient may decline any or all screening. Carrier screening and counseling ideally should be performed before pregnancy because this enables couples to learn about their reproductive risk and consider the most complete range of reproductive options, including whether or not to become pregnant and whether to use advanced reproductive technologies such as preimplantation genetic diagnosis or use of donor gametes. Knowledge during pregnancy allows patients to consider prenatal diagnosis and pregnancy management options in the event of an affected fetus.

If an individual is found to be a carrier for a specific condition, the individuals reproductive partner should be offered testing in order to receive informed genetic counseling about potential reproductive outcomes. Concurrent screening of the patient and her partner is suggested if there are time constraints for decisions about prenatal diagnostic evaluation. If both partners are found to be carriers of a genetic condition, genetic counseling should be offered. Prenatal diagnosis and advanced reproductive technologies to decrease the risk of an affected offspring should be discussed. Prenatal carrier screening does not replace newborn screening, nor does newborn screening replace the potential value of prenatal carrier screening.

When an individual is found to be a carrier for a genetic condition, the individuals relatives are at risk of carrying the same mutation. The patient should be encouraged to inform his or her relatives of the risk and the availability of carrier screening. The obstetriciangynecologist or other health care provider should not disclose this information without permission from the patient.

It is important to obtain the family history of the patient and, if possible, her partner as a screening tool for inherited risk. The family history should include the ethnic background of family members as well as any known consanguinity (a union between two individuals who are second cousins or closer in family relationship) 1*. Individuals with a positive family history of a genetic condition should be offered carrier screening for the specific condition and may benefit from genetic counseling. Ideally, information on the specific mutation will be available to aid testing and counseling.

Carrier screening for a particular condition generally should be performed only once in a persons lifetime, and the results should be documented in the patients health record. Because of the rapid evolution of genetic testing, additional mutations may be included in newer screening panels. The decision to rescreen a patient should be undertaken only with the guidance of a genetics professional who can best assess the incremental benefit of repeat testing for additional mutations.

Although several different strategies for screening are available and reviewed in Committee Opinion No. 690,Carrier Screening in the Age of Genomic Medicine, this document seeks to provide information about the different conditions for which a patient may seek prepregnancy carrier screening. If a patient requests carrier screening for a particular condition for which testing is readily available and which reasonably would be considered in another screening strategy, the requested test should be offered to her (regardless of ethnicity and family history) after counseling on the risks, benefits, and limitations of screening. The cost of carrier screening for an individual condition may be higher than the cost of testing through commercially available expanded carrier screening panels. When selecting a carrier screening approach, the cost of each option to the patient and the health care system should be considered.

What follows is a detailed discussion of some of the more common genetic conditions for which carrier screening is recommended in at least some segments of the population. The different sections collect topics that had previously been discussed in separate Committee Opinions to show how the aforementioned general principles are used and reflected in carrier screening for specific genetic conditions.

Spinal muscular atrophy, also known as SMA, is an autosomal recessive disease characterized by degeneration of spinal cord motor neurons that leads to atrophy of skeletal muscle and overall weakness. The disorder is caused by a mutation in the gene known as the survival motor neuron gene (SMN1), which is responsible for the production of a protein essential to motor neuron function. Because of the severity and relatively high carrier frequency, there has been increasing interest in carrier screening for spinal muscular atrophy in the general prenatal population 3. The genetics of spinal muscular atrophy are complex and, because of limitations in the molecular diagnostic assays available, precise prediction of the phenotype in affected fetuses may not be possible.

The incidence of spinal muscular atrophy is approximately 1 in 6,000 to 1 in 10,000 live births, and the disease is reported to be the leading genetic cause of infant death. Carrier frequencies in most populations are estimated at 1 in 40 to 1 in 60, but carrier frequencies appear to be lower in the Hispanic population (1:117) 4. Carrier frequencies and residual risks are outlined by ethnicity in Table 1. Approximately 2% of cases of spinal muscular atrophy are the result of a new gene mutation. There is no effective treatment for the disease.

There are several types of spinal muscular atrophy based on age at symptom onset. Earlier onset is correlated with more severe manifestations. The most severe and most common form of the disease, type I (WerdnigHoffman), has symptomatic onset before 6 months of age and causes death from respiratory failure within the first 2 years of life. Type II spinal muscular atrophy is of intermediate severity, with typical onset before 2 years of age. Affected children are able to sit, but few are able to stand or walk unaided. Respiratory insufficiency is a frequent cause of death during adolescence; however, the lifespan of patients with spinal muscular atrophy type II varies from age 2 years to the third decade of life. More than 80% of cases of spinal muscular atrophy are type I or type II, both of which are lethal forms. A milder form, type III (KugelbergWelander), has typical symptomatic onset after 18 months of age. However, the symptom profile is quite variable. Affected individuals typically reach all major motor milestones, but function ranges from requiring wheelchair assistance in childhood to completely unaided ambulation into adulthood with minor muscular weakness. Many patients have normal life expectancies. Type IV has onset in adulthood. There is an additional Type 0 proposed, which has onset in the prenatal period.

There are two nearly identical survival motor neuron genes present in humans, known as SMN1 and SMN2. SMN1 is considered the active gene for survival motor neuron protein production, and more than 98% of patients with spinal muscular atrophy have an abnormality in both SMN1 genes, which can be caused by a deletion (95%) of exon 7, or other mutation. There is generally one copy of SMN1 per chromosome, but occasionally two can be located on the same chromosome. A variable number of SMN2 gene copies (ranging from zero to three) may be present, but the SMN2 gene produces only a small amount of functional survival motor neuron protein. A higher number of SMN2 copies correlates with generally milder clinical phenotypes, but accurate prediction of the spinal muscular atrophy phenotype based on SMN2 copy number is not possible 5.

For diagnosis of spinal muscular atrophy in a child or an adult, it is sufficient to simply detect the classic SMN1 deletion using DNA analysis in both SMN1 alleles. This is approximately 95% sensitive (100% specific) for patients with clinical features suspicious for spinal muscular atrophy. However, this approach is not sufficient to identify patients who are heterozygous, or carriers, for the SMN1 deletion. Carrier testing requires a quantitative polymerase chain reaction assay that provides a measure of SMN1 copy number. Detection of a single normal copy of SMN1 would indicate the carrier state Figure 1. There are limitations, however, to the use of this assay to determine carrier status. Approximately 34% of the general population have two SMN1 copies on one chromosome and no copies on the other and will not be identified as being a carrier of spinal muscular atrophy using this approach. These individuals are carriers because one of their chromosomes is missing the SMN1 allele. The missing SMN1 allele appears to be more predominant in African Americans and lowers the carrier detection rate to approximately 71% in this group. In other ethnic groups, more than 90% of carriers are detected by dosage analysis of SMN1. Another 2% of the general population has SMN1 mutations that are not detectable by dosage analysis. Therefore, the counseling of patients who are tested for carrier status must account for the residual risk present when carrier screening assay results are negative, particularly in patients from families affected by spinal muscular atrophy.

Screening for spinal muscular atrophy should be offered to all women who are considering pregnancy or are currently pregnant and have had appropriate counseling about the possible range of severity, carrier rate, and detection rate. Posttest counseling should reiterate residual risk after negative screening based on the number of SMN1 copies present. In patients with a family history of spinal muscular atrophy, molecular testing reports of the affected individual and carrier testing of the related parent should be reviewed, if possible, before testing to determine the residual risk for the patient with a negative screen. If the reports are not available, SMN1 deletion testing should be recommended for the low-risk partner. If this individual is found to be a carrier, the couple should be referred for further genetic counseling and consideration of further genetic testing in the high-risk partner.

Prepregnancy and prenatal carrier screening for cystic fibrosis, also known as CF, was introduced into routine obstetric practice in 2001 6. The goal of cystic fibrosis carrier screening is to identify individuals at risk of having a child with classic cystic fibrosis, which is defined by significant pulmonary disease and pancreatic insufficiency. Cystic fibrosis is more common among the non-Hispanic white population compared with other racial and ethnic populations; however, because of the increasing difficulty in assigning a single ethnicity to individuals, in 2005, the American College of Obstetricians and Gynecologists recommended offering cystic fibrosis carrier screening to all patients.

Cystic fibrosis is the most common life-threatening, autosomal recessive condition in the non-Hispanic white population. The disease incidence is 1 in 2,500 individuals in the non-Hispanic white population and considerably less in other ethnic groups. It is a progressive, multisystem disease that primarily affects the pulmonary, pancreatic, and gastrointestinal systems but does not affect intelligence. The current median predicted survival is approximately 42 years, with respiratory failure as the most common cause of death 7. More than 95% of males with cystic fibrosis have primary infertility with obstructive azoospermia secondary to congenital bilateral absence of the vas deferens. Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene, located on chromosome 7. Two copies of deleterious mutations in this gene cause cystic fibrosis.

The sensitivity of the screening test varies among ethnic groups Table 2, ranging from less than 50% in those of Asian ancestry to 94% in the Ashkenazi Jewish population 8. Therefore, screening is most efficacious in non-Hispanic white and Ashkenazi Jewish populations. Because screening is offered for only the most common mutations, a negative screening test result reduces but does not eliminate the chance of being a cystic fibrosis carrier and having an affected offspring. Therefore, if a patient is screened for cystic fibrosis and has a negative test result, she still has a residual risk of being a carrier. The most common cystic fibrosis carrier frequencies, as well as the rates of residual carrier risk after a negative test result, are listed by racial and ethnic group in Table 2.

As with all carrier screening, it is generally more cost effective and practical to perform initial carrier screening only for the patient. Cystic fibrosis carrier screening should be offered to all women who are considering pregnancy or are currently pregnant. If the patient is a cystic fibrosis carrier, then her partner should be tested. During pregnancy, concurrent screening of the patient and her partner is suggested if there are time constraints for decisions regarding prenatal diagnostic evaluation. Given that cystic fibrosis screening has been a routine part of reproductive care for women since 2001, it is prudent to determine if the patient has been previously screened before ordering repeat cystic fibrosis screening. If a patient has been screened previously, cystic fibrosis screening results should be documented, but the test should not be repeated. Although some mutation panels have been expanded over the past decade, the incremental yield of the addition of those mutations is small for most patients. Before repeat testing, the clinical scenario should be discussed with an obstetriciangynecologist or other health care provider with expertise in genetics.

The following are various carrier screening scenarios with associated management recommendations:

A woman is a carrier of a cystic fibrosis mutation and her partner is unavailable for testing or paternity is unknown. Genetic counseling to review the risk of having an affected child and prenatal testing options and limitations is recommended.

Prenatal diagnosis is being performed for other indications and cystic fibrosis carrier status is unknown. Cystic fibrosis screening can be performed concurrently on the patient and partner. Chorionic villi or amniocytes may be maintained in culture by the diagnostic laboratory until cystic fibrosis screening results are available for the patient or couple. If both partners are carriers, diagnostic testing for cystic fibrosis can be performed on the chorionic villi or amniocytes.

Both partners are cystic fibrosis carriers. Genetic counseling is recommended to review prenatal testing and reproductive options. Prenatal diagnosis should be offered for the couples specific, known mutations.

Both partners are unaffected, but one or both has a family history of cystic fibrosis. Genetic counseling and medical record review should be performed to determine if CFTR mutation analysis in the affected family member is available. Carrier screening should be offered for both partners, with attention to ensure that the familial mutation is included in the assessment.

A womans reproductive partner has cystic fibrosis or apparently isolated congenital bilateral absence of the vas deferens. The couple should be provided follow-up genetic counseling by an obstetriciangynecologist or other health care provider with expertise in genetics for mutation analysis and consultation.

An individual has two cystic fibrosis mutations but has not previously received a diagnosis of cystic fibrosis. The individual usually has a mild form of the disease and should be referred to a specialist for further evaluation. Genetic counseling is recommended.

To date, more than 1,700 mutations have been identified for cystic fibrosis 9. Current guidelines, revised by the American College of Medical Genetics and Genomics in 2004, recommend use of a panel that contains, at a minimum, the 23 most common mutations. The guidelines were developed after assessing the initial experiences following the implementation of cystic fibrosis screening into clinical practice 10. A number of expanded mutation panels are now commercially available and can be considered to enhance the sensitivity for carrier detection, especially in non-Caucasian ethnic groups. Cystic fibrosis screening also may identify the 5T/7T/9T variants in the CFTR gene. Although not disease-causing on their own, these variants can be associated with milder forms of disease and male infertility in individuals who are heterozygous for certain CFTR gene mutations. Genetic counseling is important to discern whether the combination of mutations and variants would cause classic or atypical cystic fibrosis.

Complete analysis of the CFTR gene by DNA sequencing is not appropriate for routine carrier screening. This type of testing generally is reserved for patients with cystic fibrosis, patients with negative carrier screening result but a family history of cystic fibrosis (especially if family test results are not available), males with congenital bilateral absence of the vas deferens, or newborns with a positive newborn screening result when mutation testing (using the standard 23-mutation panel) has a negative result. Because carrier screening detects most mutations, sequence analysis should be considered only after discussion with a genetics professional to determine if it will add value to the standard screening that was performed previously.

All states include cystic fibrosis screening as part of their newborn screening panel. However, newborn screening panels do not replace prepregnancy or prenatal carrier screening. Because these screening programs generally identify affected newborns, a negative test result in an unaffected newborn provides no information about the carrier status of the parents. Thus, it is important that cystic fibrosis screening continues to be offered to women who are considering pregnancy or are currently pregnant.

Hemoglobin consists of four interlocking polypeptide chains, each of which has an attached heme molecule. Adult hemoglobin consists of two -chains and either two-chains (hemoglobin A), two -chains (hemoglobin F), or two -chains (hemoglobin A2). Alpha-globin chain production begins in the first trimester and is an essential component of fetal hemoglobin F, hemoglobin A, and hemoglobin A2. Hemoglobin F is the primary hemoglobin of the fetus from 12 weeks to 24 weeks of gestation. In the third trimester, production of hemoglobin F decreases as production of -chains and hemoglobin A begins.

Sickle cell disease refers to a group of autosomal recessive disorders that involve abnormal hemoglobin (hemoglobin S). Hemoglobin S differs from the normal hemoglobin A because of a single nucleotide substitution in the -globin gene; this alteration causes a substitution of valine for glutamic acid in the number six position of the -globin polypeptide. Asymptomatic individuals with heterozygous hemoglobin S genotypes (carriers) are said to have sickle cell trait. The most severe form of the disease, hemoglobin SS (homozygous hemoglobin S), is called sickle cell anemia.

Sickle cell disorders are found not only in patients who have the hemoglobin genotype SS, but also in those who have hemoglobin S and another abnormality of -globin structure or -globin production. The most common of these are hemoglobin SC disease and hemoglobin S/-thalassemia. In hemoglobin C, the same nucleotide involved in the hemoglobin S mutation is altered, but the nucleotide change results in the amino acid substitution of lysine for glutamic acid. This and other abnormal hemoglobins, when inherited with hemoglobin S, may cause clinically significant vasoocclusive phenomena and hemolytic anemia similar to hemoglobin SS.

Sickle cell disease occurs most commonly in people of African origin. Approximately 1 in 10 African Americans has sickle cell trait 11. One in every 300500 African-American newborns has some form of sickle cell disease. Hemoglobin S also is found in high frequency in other populations such as Greeks, Italians (particularly Sicilians), Turks, Arabs, Southern Iranians, and Asian Indians 12.

The classical clinical feature of patients with sickle cell disease is seen under conditions of decreased oxygen tension, in which the red blood cells become distorted into various shapes, some of which resemble sickles. The distorted red cells lead to increased viscosity, hemolysis, and anemia and a further decrease in oxygenation. When sickling occurs within small blood vessels, it can interrupt blood supply to vital organs (vasoocclusive crisis).Repeated vasoocclusive crises result in widespread microvascular obstruction with interruption of normal perfusion and function of several organs, including the spleen, lungs, kidneys, heart, and brain. These crises are extremely painful and typically require hospitalization and medical management. Over the course of their lifetimes, patients with sickle cell disease who have repeated crises often build up tolerance to opioid medications and may require large doses in order to achieve relief from the pain of an acute vasoocclusive crisis. Also, these patients often have an element of chronic pain and they may require daily pain medication even in the absence of an acute crisis. Adults with hemoglobin SS are functionally asplenic, having undergone autosplenectomy by adolescence. Absence of the spleen contributes to the increased incidence and severity of infection in patients with sickle cell disease.

The most significant threat to patients with sickle cell disease is acute chest syndrome. Acute chest syndrome is characterized by a pulmonary infiltrate with fever that leads to hypoxemia and acidosis. The infiltrates are not infectious in origin but rather are due to vasoocclusion from sickling or embolization of marrow from long bones affected by sickling 13.

The diagnosis of hemoglobinopathies, including sickle cell disorders, is made by hemoglobin electrophoresis. In the homozygous form of sickle cell disease, nearly all the hemoglobin is hemoglobin S with small amounts of hemoglobin A2 and hemoglobin F. Heterozygous sickle cell trait (hemoglobin AS) is identified by a larger percentage of hemoglobin A and an asymptomatic course. Solubility tests alone are inadequate for diagnosis of sickle cell disorders because they cannot distinguish between the heterozygous AS and homozygous SS genotypes. Solubility tests are not useful for screening because of the inability to identify other pathologic variants such as hemoglobin C, hemoglobin E, and -thalassemia trait.

The thalassemias represent a wide spectrum of hematologic disorders that are characterized by a reduced synthesis of globin chains, which results in microcytic anemia. Thalassemias are classified according to the globin chain affected, with the most common types being -thalassemia and -thalassemia 14.

Alpha-thalassemia usually results from a gene deletion of two or more copies of the four -globin genes. Deletion of one -globin gene (-/) is clinically unrecognizable, and laboratory testing yields normal results. Deletion of two -globin genes causes -thalassemia trait, a mild asymptomatic microcytic anemia. The deletions can be on the same chromosome or in cis (/--), or on each chromosome or in trans (--).

Individuals with these gene deletions are referred to as carriers and are at an increased risk of having children with a more severe form of thalassemia caused by deletions of three or four copies of the -globin gene (-thalassemia major). The possible genetic combinations are summarized in Table 3.

Alpha-thalassemia trait (-thalassemia minor) is common among individuals of Southeast Asian, African, and West Indian descent and in individuals with Mediterranean ancestry. Individuals with Southeast Asian ancestry are more likely to carry two gene deletions in cis or on the same chromosome (--) and are at an increased risk of offspring with hemoglobin Bart or hemoglobin H disease. Hemoglobin H disease, which is caused by the deletion of three -globin genes, usually is associated with mild-to-moderate hemolytic anemia. Alpha-thalassemia major (hemoglobin Bart) results in the absence of -globin (--/--), which is associated with hydrops fetalis, intrauterine death, and preeclampsia 12.

Beta-thalassemia is the result of a mutation in the -globin gene that causes deficient or absent -chain production, which in turn causes an absence of hemoglobin A. Individuals of Mediterranean, Asian, Middle Eastern, Hispanic, and West Indian descent are more likely to carry -thalassemia mutations. Classification of -thalassemias is based on a description of the molecular mutation or on clinical manifestations. Individuals who are heterozygous for this mutation have -thalassemia minor. Those who are homozygous have -thalassemia major (Cooleys anemia) or a milder form called thalassemia intermedia. There are numerous mutations associated with -thalassemia, and each mutation can have a different effect on the amount of -chain produced. Because of the many different mutations, many individuals with -thalassemia major are actually compound heterozygotes carrying two different mutations. Beta-thalassemia major is characterized by severe anemia with resultant extramedullary erythropoiesis, delayed sexual development, and poor growth. Elevated levels of hemoglobin F in individuals with -thalassemia major partially compensate for the absence of hemoglobin A; however, death usually occurs by age 10 years unless treatment is begun early with periodic blood transfusions. With transfusion, the severe anemia is reversed and extramedullary erythropoiesis is suppressed. In homozygotes with the less severe +-thalassemia mutations, often referred to as -thalassemia intermedia, variable but decreased amounts of -chains are produced and as a result variable amounts of hemoglobin A are produced. Some individuals can inherit a hemoglobin S mutation from one parent and a -thalassemia mutation from the other. The expression of the resulting hemoglobin S/-thalassemia is determined by the type of -thalassemia mutation 15.

A combination of laboratory tests may be required to provide the information necessary to counsel couples who are carriers of one of the thalassemias or sickle cell disease. To ensure accurate hemoglobin identification, which is essential for genetic counseling, a complete blood count with red blood cell indices should be performed in all women who are currently pregnant to assess not only their risk of anemia but also to allow assessment for risk of a hemoglobinopathy. If red blood cell indices indicate a low mean corpuscular hemoglobin or mean corpuscular volume, hemoglobin electrophoresis also should be performed. A hemoglobin electrophoresis should be performed in addition to a complete blood count if there is suspicion of hemoglobinopathy based on ethnicity (African, Mediterranean, Middle Eastern, Southeast Asian, or West Indian descent). Ideally, this testing also should be offered to women before pregnancy. If the results of a prior hemoglobin electrophoresis are available, repeat hemoglobin electrophoresis is not necessary to evaluate status.

Several tests, including solubility testing (such as a test for the presence of hemoglobin S), isoelectric focusing, and high-performance liquid chromatography, have been used for primary screening. However, solubility tests are inadequate for screening and fail to identify important transmissible hemoglobin gene abnormalities that affect fetal outcome (eg, hemoglobin C trait, -thalassemia trait, hemoglobin E trait). Many individuals with these genotypes are asymptomatic, but if their partners have the sickle cell trait or other hemoglobinopathies, they may produce offspring with more serious hemoglobinopathies, such as hemoglobin S/-thalassemia and hemoglobin sickle cell disease.

Determination of mean corpuscular volume is recommended to assess risk of -thalassemia or -thalassemia. Patients who have a low mean corpuscular volume (less than 80 fL) may have one of the thalassemia traits, and hemoglobin electrophoresis should be performed if it was not done previously. These individuals also may have iron deficiency anemia, and measurement of serum ferritin levels is recommended. Beta-thalassemia is associated with elevated hemoglobin F and elevated hemoglobin A2 levels (more than 3.5%). Neither hemoglobin electrophoresis nor solubility testing can identify individuals with -thalassemia trait; only molecular genetic testing can identify this condition. If the mean corpuscular volume is below normal, iron deficiency anemia has been excluded, and the hemoglobin electrophoresis is not consistent with -thalassemia trait (ie, there is no elevation of Hb A2 or Hb F), then DNA-based testing should be used to detect -globin gene deletions characteristic of-thalassemia. The hematologic features of some of the common hemoglobinopathies are shown in Table 4. If both partners are identified as carriers of a gene for abnormal hemoglobins, genetic counseling is recommended.

Couples at risk of having a child with a hemoglobinopathy may benefit from genetic counseling to review their risk, the natural history of these disorders, prospects for treatment and cure, availability of prenatal genetic testing, and reproductive options. Prenatal diagnostic testing for the mutation responsible for sickle cell disease is widely available. Testing for -thalassemia and -thalassemia is possible if the mutations and deletions have been previously identified in both parents. These DNA-based tests can be performed using chorionic villi obtained by chorionic villus sampling or using cultured amniotic fluid cells obtained by amniocentesis. For some couples, preimplantation genetic diagnosis in combination with in vitro fertilization may be a desirable alternative to avoid termination of an affected pregnancy. Preimplantation genetic diagnosis has been successfully performed for sickle cell disease and most types of -thalassemia.

Fragile X syndrome is the most common inherited form of intellectual disability. The syndrome occurs in approximately 1 in 3,600 males and 1 in 4,0006,000 females from a variety of ethnic backgrounds. Intellectual disability or impairment ranges from borderline, including learning disabilities, to severe, presenting with cognitive and behavioral disabilities, including autism with intellectual disability; attention deficithyperactivity disorder; or both. Most affected males have significant intellectual disability. Fragile X syndrome is a common known cause of autism or autism spectrum disorder behaviors with intellectual disability, with the diagnosis occurring in approximately 25% of affected individuals 16. Other associated phenotypic abnormalities include distinctive facial features in males (including a long, narrow face and prominent ears), enlarged testicles (macroorchidism), joint and skin laxity, hypotonia, mitral valve prolapse, delay in speech, and delay in gross and fine motor skills. The abnormal facial features are subtle in infancy and become more noticeable with age, making phenotypic diagnosis difficult, especially in the newborn. Affected females may have a milder phenotype, and it is sometimes hard to establish the diagnosis based on clinical findings alone.

Fragile X syndrome is transmitted as an X-linked disorder. However, the molecular genetics of the syndrome are complex. The disorder is caused by expansion of a repeated trinucleotide segment of DNA, cytosineguanineguanine that leads to altered transcription of the fragile X gene FMR1. The number of cytosineguanineguanine repeats varies among individuals and has been classified into four groups depending on the repeat size: 1) unaffected (544 repeats), 2) intermediate (4554 repeats), 3) premutation (55200 repeats), and 4) full mutation (greater than 200 repeats) 17 18 Table 5.

A person with 55200 repeats does not have features associated with fragile X syndrome but is at increased risk of fragile X-associated tremor/ataxia syndrome (also known as FXTAS) and FMR1-related premature ovarian failure. When more than 200 repeats are present, an individual has a full mutation that results in the full expression of fragile X syndrome in males and variable expression in females. The large number of repeats in a full mutation allele causes the FMR1 gene to become methylated and inactivated.

Transmission of a disease-producing mutation to a fetus depends on the sex of the parent transmitting the mutation and the number of cytosineguanineguanine repeats present in the parental gene. Repeats very rarely expand during spermatogenesis in the male, such that only an affected male can transmit the full mutation to his female offspring. However, repeats in the female may expand during oogenesis, such that women with the premutation may transmit a full mutation, which results in an affected child. The larger the size of the premutation repeat, the more likely that there will be expansion to a full mutation Table 5. Women with an intermediate number of triplet repeats (4554) do not transmit a full mutation to their male and female offspring, although there may be expansion to a premutation allele in their offspring. Diagnosis of mutation size may vary by as many as 3 or 4 repeats. The frequency of premutation allele carriers (repeat size greater than 54) in the population has been reported to be as high as 1 in 157 in a large Israeli study of women (more than 36,000 individuals) without a family history of intellectual disability or developmental abnormalities 19. The most recent prevalence data from the United States reported a carrier frequency of 1 in 86 for those with a family history of intellectual disability and 1 in 257 for women with no known risk factors for fragile X syndrome 20.

Fragile X premutation carrier screening is recommended for women with a family history of fragile X-related disorders or intellectual disability suggestive of fragile X syndrome and who are considering pregnancy or are currently pregnant. If a woman has unexplained ovarian insufficiency or failure or an elevated follicle-stimulating hormone level before age 40 years, fragile X carrier screening is recommended to determine whether she has an FMR1 premutation. Although following these guidelines will not detect most premutation carriers in the population, the guidelines do target a higher prevalence group based on current data with regard to carrier frequency. If a patient with no family history requests fragile X screening, it is reasonable to offer screening after informed consent. All identified individuals with intermediate results and carriers of a fragile X premutation or full mutation should be provided follow-up genetic counseling to discuss the risk to their offspring of inheriting an expanded full-mutation fragile X allele and to discuss fragile X-associated disorders (premature ovarian insufficiency and fragile X tremor/ataxia syndrome).

Prenatal diagnostic testing for fragile X syndrome should be offered to known carriers of the fragile X premutation or full mutation. Fetal DNA analysis from amniocentesis or chorionic villus sampling reliably determines the number of triplet repeats. However, there are caveats in interpretation of chorionic villus sampling results: in some cases, an analysis of FMR1 gene methylation in full mutations from samples of chorionic villi may not be accurate, and a follow-up amniocentesis is necessary to accurately determine the methylation status of the gene 21. These limitations should be discussed with an obstetriciangynecologist or other health care provider with the requisite genetics expertise before ordering any testing. DNA-based molecular analysis (eg, Southern blot analysis and polymerase chain reaction) is the preferred method of diagnosis of fragile X syndrome and of determining FMR1 triplet repeat number (eg, premutations). In rare cases, the size of the triplet repeat and the methylation status do not correlate, which makes it difficult to predict the clinical phenotype. In cases of this discordance, the patient should be referred to a genetics professional.

A number of clinically significant, autosomal recessive disease conditions are more prevalent in individuals of Ashkenazi Jewish (Eastern European and Central European) descent. Most individuals of Jewish ancestry in North America are descended from Ashkenazi Jewish communities and, thus, are at increased risk of having offspring with one of these conditions. When only one partner is of Ashkenazi Jewish descent, that individual should be offered screening first. If it is determined that this individual is a carrier, the other partner should be offered screening. However, the couple should be informed that the carrier frequency and the detection rate in non-Jewish individuals are unknown for most of these disorders, except for TaySachs disease and cystic fibrosis. Therefore, it is difficult to accurately predict the couples risk of having a child with the disorder.

The American College of Obstetricians and Gynecologists has previously recommended offering carrier screening for four conditions in the Ashkenazi population:

Canavan disease is a severe degenerative neurologic disease. The phenotype is quite variable, but patients typically present in the first few months of life with delayed motor milestones (eg, head control and sitting). They will manifest macrocephaly, hypotonia, and intellectual disability. Life expectancy is variable, but many individuals die in childhood or adolescence. Treatment is primarily supportive because there is no cure. The disease is caused by mutations in the gene for aspartoacylase, which is involved in the metabolism of N-acetyl-L aspartic acid.

Cystic fibrosis is discussed elsewhere in this document.

Familial dysautonomia, a disorder of the sensory and autonomic nervous system, is associated with significant morbidity. Clinical features include abnormal suck and feeding difficulties, episodic vomiting, abnormal sweating, pain and temperature insensitivity, labile blood pressure levels, absent tearing, and scoliosis. Treatment is available that can improve the length and quality of life, but there currently is no cure. In 2001, the gene for familial dysautonomia was identified. At least two mutations in the familial dysautonomia gene, IKBKAP, have been identified in patients of Ashkenazi Jewish descent with familial dysautonomia. One of the mutations, IVS20(+6T->C), is found in more than 99% of patients with familial dysautonomia. It occurs almost exclusively in individuals of Ashkenazi Jewish descent; the carrier rate (1 in 32) is similar to TaySachs disease and cystic fibrosis 22.

TaySachs disease is discussed elsewhere in this document.

Some experts have advocated for a more comprehensive screening panel for those of Ashkenazi descent, including tests for several diseases that are less common (carrier rates 1 in 15 to 1 in 168). The following is a list of autosomal recessive conditions for which screening should be considered in individuals of Ashkenazi descent:

Bloom syndrome is characterized by short stature, skin rash with sun exposure, and increased risk of cancer of any type. Affected individuals often have a high-pitched voice, distinctive facial features, learning disabilities, increased risk of diabetes, and chronic obstructive pulmonary disease. It is caused by mutations in the BLM gene, which codes for a protein family known as the RecQ helicases.

Familial hyperinsulinism is a condition in which the pancreas produces too much insulin, which results in low blood sugar caused by mutations in the ABCC8 gene.

Fanconi anemia can be caused by mutations in at least 15 different genes, but 8090% of cases are due to mutation in one of three genes: 1) FANCA, 2) FANCC, and 3) FANCG. Affected individuals can experience bone marrow failure; increased risk of cancer, including leukemia and solid tumors; and structural defects such as short stature, skin pigment changes, nervous system abnormalities (including central nervous system malformations), eye and ear malformations and hearing loss, skeletal abnormalities in particular affecting the thumb or forearms, gastrointestinal abnormalities (including effects on the oral cavity), and others. Of note, 2540% of affected individuals do not have any physical abnormalities 23.

Gaucher disease is caused by mutations in the GBA gene, which codes for the enzyme beta-glucocerebrosidase; this enzyme is responsible for the metabolism of glucocerebroside into glucose and ceramide. There are multiple types. Type 1 is the most common and does not affect the central nervous system. The symptoms can range from mild to severe and may not present until adulthood. Individuals present with hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and bone abnormalities. Type 2 and type 3 Gaucher disease cause the aforementioned symptoms and signs and affect the central nervous system, including abnormal eye movement, seizures, and brain damage. Individuals with Type 2 can experience life-threatening issues early in life. There is also a perinatal lethal form, which can cause complications that manifest before birth or early in infancy. Finally, there is a cardiovascular type, which is characterized by calcification of the cardiac valves.

Glycogen storage disease type I (also known as von Gierke disease) is caused by the buildup of glycogen in body cells, particularly the liver, kidneys, and small intestine, and leads to malfunction of these organs. The signs and symptoms present early in life, approximately age 34 months.

Joubert syndrome is caused by mutations in genes related to the structure and function of cilia. Manifestations include the molar tooth sign on magnetic resonance imaging of the brain, which indicates abnormal development of the brainstem and cerebellar vermis; infants also can have hypotonia and ataxia, unusually fast or slow breathing, intellectual disability, and developmental delays.

Maple syrup urine disease is caused by mutations in the BCKDHA, BCKDHB, and DBT genes, which encode proteins that are essential for breaking down the amino acids leucine, isoleucine, and valine. The urine of affected infants has a distinctive sweet odor. Affected individuals manifest poor feeding, lethargy, and developmental delays. Without treatment, this condition can be lethal.

Mucolipidosis type IV is caused by mutations in the MCOLN1 gene, which is involved in the function of lysosomes; dysfunction of this gene leads to accumulation of lipids and proteins in lysosomes. Affected individuals have severe psychomotor delays and visual impairment.

NiemannPick disease can present in a variety of ways, with affected individuals exhibiting a range of severity. There are four main types: 1) A, 2) B, 3) C1, and 4) C2. Those with type A have a cherry-red spot in the eye; they often have failure to thrive, and at approximately age 1 year begin to exhibit psychomotor regression and widespread lung damage. Most do not survive beyond early childhood. Type A is the most common form in the Jewish population. Types B, C1, and C2 are not as severe as type A and present later in childhood, although all three can manifest with lung disease. Individuals with types C1 and C2 develop neurologic compromise that eventually interferes with feeding ability and intellectual function.

More:
Carrier Screening for Genetic Conditions | ACOG

Posted in Genetic medicine | Comments Off on Carrier Screening for Genetic Conditions | ACOG

New NHS genetic testing service could save thousands of children in England – The Guardian

Posted: October 13, 2022 at 2:26 am

Very sick babies and children will be diagnosed and start treatment more quickly thanks to a revolutionary new genetic testing service being launched by the NHS.

Doctors will gain vital insights within as little as two days into what illnesses more than 1,000 newborns and infants a year in England have from the rapid analysis of blood tests.

Until now, when doctors suspected a genetic disorder, such tests have sometimes taken weeks as they had to be done in a sequential order to rule out other possible diagnoses, delaying treatment.

NHS England bosses say the service could save the lives of thousands of seriously ill children over time and will usher in a new era of genomic medicine.

The clinical scientists, genetic technologists and bioinformaticians will carry out much faster processing of DNA samples, including saliva and other tissue samples as well as blood. They will share their findings with medical teams and patients families.

They will undertake whole genome sequencing in a quest to identify changes in the childs DNA and so diagnose conditions such as cancer and rare genetic disorders.

While such testing is available in parts of other countries such as the US and Australia, NHS England said that its new service will be the first in the world to cover an entire country. Wales also has a similar service but it is more limited in its scope than the new service in England.

This global first is an incredible moment for the NHS and will be revolutionary in helping us to rapidly diagnose the illnesses of thousands of seriously ill children and babies, saving countless lives in the years to come, said Amanda Pritchard, NHS Englands chief executive.

The new national rapid whole genome sequencing service will be based in Exeter as part of the NHSs existing Genomic Medicine Service which is based there. It follows a successful trial in some parts of England.

Dr Emma Baple, who is running the new service, said it will transform how rare genetic conditions are diagnosed. It is a new national test being offered with results delivered inside seven days as compared to a much longer turnaround time.

It is the only test in the NHS that looks at all 22,000 genes in the human genome and all the parts in between the genes. Eighty-five per cent of all changes that lead to disease are in the genes themselves, whilst the rest is caused by the bits of DNA in between.

Test results should be available in anything between two and seven days, depending on the complexity of the childs condition, though that should get faster as technology improves, Baple added.

We know that with prompt and accurate diagnosis conditions could be cured or better managed with the right clinical care, which would be life-altering and potentially life-saving for so many seriously unwell babies and children.

Continue reading here:
New NHS genetic testing service could save thousands of children in England - The Guardian

Posted in Genetic medicine | Comments Off on New NHS genetic testing service could save thousands of children in England – The Guardian

Vertex, after setbacks, moves forward with second-generation rare disease drug – BioPharma Dive

Posted: October 13, 2022 at 2:26 am

Vertex Pharmaceuticals is trying again at developing a drug for the rare, genetic disease alpha-1 antitrypsin deficiency after two earlier efforts fell short.

The biotech announced Tuesday that it has received clearance from the Food and Drug Administration to begin a clinical trial testing a new treatment for the condition, which is caused by the misfoldingof a protein called AAT and damages the lungs and liver of affected individuals.

The study, which will enroll healthy volunteers, is a Phase 1 trial designed to measure the drugs safety and find an appropriate dose for further testing.

In addition, Vertex said it will also begin a nearly year-long Phase 2 study of an earlier drug that wasnt potent enoughto advance into late-stage testing.While technically positive, the magnitude of treatment benefit observed in a mid-stage trial last year wasnt as large as Vertex was looking for. Further analysis of the study showed the drug reduced levels of a liver polymer in the blood of patients, however.

The new study will assess the effect of longer-term treatment on polymer clearance and whether it also yields greater increases in functional AAT protein.

By simultaneously advancing new, more potent molecules into the clinic and assessing the impact of longer-duration treatment, we expect to have both the assets and the data necessary to progress our AAT corrector program in 2023, said David Altshuler, Vertexs head of research and chief scientific officer, in the companys Tuesday statement.

Alpha-1 antitrypsin deficiency is one of several conditions Vertex has targeted in its efforts to build a pipeline of medicines that go beyond its historical focus on cystic fibrosis. While the drugs Vertex has made for the lung disease are clinically and commercially successful, pressure has increased for the company to prove it can do the same elsewhere.

It has some recent successes in that quest, reporting positive results for drugs to treat pain, kidney disease and Type 1 diabetes. Those findings have helped Vertex shares climb to all-time highs this year. Alpha-1 antitrypsin deficiency has been harder, though. Vertex stopped testingits first compound for the disease after reports of an early safety signal.

"Given the performance of the previous-gen AAT molecules, we think this is still a show-me story where we need to see strong efficacy data before making any conclusions," wrote Michael Yee, an analyst at Jefferies, in a Tuesday note to clients.

Vertex is also nearing submission of approval applications for a gene editing medicine its developing with CRISPR Therapeutics for sickle cell disease and beta thalassemia.

Read this article:
Vertex, after setbacks, moves forward with second-generation rare disease drug - BioPharma Dive

Posted in Genetic medicine | Comments Off on Vertex, after setbacks, moves forward with second-generation rare disease drug – BioPharma Dive

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer – Yahoo Finance

Posted: October 13, 2022 at 2:26 am

Passage Bio

PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of William Chou, M.D. as chief executive officer (CEO) and a member of the board, effective immediately. Edgar B. (Chip) Cale will resign his position as the companys interim CEO and will continue in his role as general counsel and corporate secretary. Maxine Gowen, Ph.D., will step down as interim executive chairwoman following a brief transition period and will then continue to serve as chairwoman.

The Board and I are delighted to welcome Will to Passage Bio to lead the company through an exciting phase of development, said Dr. Gowen. Wills depth of experience and success in developing and commercializing advanced therapeutics will be instrumental in establishing and solidifying the company as a leader in genetic medicines.

Dr. Chou is an accomplished executive with nearly twenty years of healthcare experience across a range of development and commercialization roles. Most recently, Dr. Chou served as CEO of Aruvant Sciences, a clinical-stage biopharmaceutical company focused on developing gene therapies for rare diseases.

I am thrilled to join the talented team at Passage Bio and build upon the companys many accomplishments and impressive capabilities, said Dr. Chou. With three ongoing clinical programs, we are poised to deliver multiple meaningful milestones over the coming quarters. As a clinician, it is my privilege to lead a company with tremendous potential to bring transformative therapies to patients with CNS disorders for which there are limited or no approved treatment options today.

Prior to joining Aruvant, Dr. Chou served in a variety of leadership roles at Novartis, including vice president, global disease lead for Novartis Cell and Gene Therapy unit where he oversaw the global commercial launch of Kymriah, the first CAR-T cell therapy. Prior to that role, Dr. Chou led the Kymriah lymphoma clinical development program to approvals in the United States, Europe, Australia, Canada and Japan. Before joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy.

Story continues

Dr. Chou holds an M.B.A. from the Yale School of Management, an M.D. from the University of Pittsburgh School of Medicine, and an A.B. in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in geriatrics at Yale University.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvanias Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at http://www.passagebio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones, including initiation of clinical trials and the availability of clinical data from such trials; our expectations about our collaborators and partners ability to execute key initiatives; our expectations about manufacturing plans and strategies; our expectations about cash runway; and the ability of our lead product candidates to treat their respective target monogenic CNS disorders. These forward-looking statements may be accompanied by such words as aim, anticipate, believe, could, estimate, expect, forecast, goal, intend, may, might, plan, potential, possible, will, would, and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop and obtain regulatory approval for our product candidates; the timing and results of preclinical studies and clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; failure to protect and enforce our intellectual property, and other proprietary rights; our dependence on collaborators and other third parties for the development and manufacture of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; and the other risks and uncertainties that are described in the Risk Factors section in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

For further information, please contact:

Passage Bio Investors:Stuart HendersonPassage Bio267-866-0114shenderson@passagebio.com

Passage Bio Media:Mike BeyerSam Brown Inc. Healthcare Communications312-961-2502MikeBeyer@sambrown.com

Read the original post:
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance

Posted in Genetic medicine | Comments Off on Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer – Yahoo Finance

Stem cell therapy side effects & risks: infections, tumors & more

Posted: October 13, 2022 at 2:25 am

What are the possible stem cell therapy side effects of going to an unproven clinic? This is a common question I get asked. Most often it is asked by patients who reach out.

Check out the YouTube video below on our stem cell channel. If you like such videos please subscribe to our channel.

Many clinics have said over the years to potential customers that the worst that can happen is that the stem cells wont work.

We know this isnt true and its irresponsible.

Anything that has the potential to help a medical condition also poses some risks of harm. For this reason, its important to discuss potential stem cell therapy side effects. In this case I am focusing on the risks primarily associated with unproven stem cell clinics. Not for established methods like bone marrow transplantation.

Recent publications in journals including one by my colleague Gerhard Bauer and a special report by The Pew Charitable Trust have helped clarify risks. Gerhards paper presents the types of side effects that appear more common after people go to stem cell clinics. After closely following this area for a decade I was familiar with many of the examples of problems. However, some were new to me.

One of the highest profiles examples of bad outcomes was the case where three people lost their vision due to stem cells injected by a clinic.See image below of one set of damaged eyes. More on that case at the end of the post.

Why do stem cells pose risks?

Stem cells are uniquely powerful cells.

By definition they can both make more of themselves and turn into at least one other kind of specialized cells. This latter process is called differentiation. That former ability to make more of themselves is called self-renewal.

The most powerful stem cells are totipotent stem cells that can literally make any kind of differentiated cell. The fertilized human egg is the best example of a cell having totipotency. Next in the power line are pluripotent stem cells including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Adult stem cells are multipotent. The best type of stem cell depends on the condition that is trying to be treated. The best type may not be the most powerful.

In any case, the power of stem cells is a main reason they also pose risks. These cells are not always easy to control and misdirected power can do harm.

Let me explain and start with the side effect that seems scariest to most.

If someone injects a patient with stem cells, its possible that the self-renewal power of stem cells just wont get shut off. In that scenario the stem cells could drive formation of a tumor or even cancer. Note that tumors are not always malignant whereas cancer is always malignant.

Why wouldnt a transplanted stem cell always eventually hit the brakes on self-renewal? It could be that the stem cell has one or more mutations. For any stem cells grown in a lab, within the population of millions of cells in a dish, there are going to be at least a few with mutations that crop up. Thats just the way it goes with growing cells in a lab.

Even stem cells not grown in the lab have the same spectrum of mutations as the person they were isolated from. It may seem weird to think about, but we all have some mutations.

When someone like a clinic person tells us that theres a risk to you thats a one in a million chance it doesnt sound that bad. However, with cells being injected into a person in theory all it takes is one cell out of a million cells in a syringe with a couple really bad mutations to potentially cause disaster. Research suggests it takes more than one cell with cancer-causing potential to make a tumor in experiments in the lab, but in actual people we just dont know. Many cancers may arise from one stem cell gone awry. If a clinic injects 50 or 100 million cells, a one-in-a-million rate of dangerous cells means that 50-100 such cells end up in the patient.

The odds are far lower for cells never grown in a lab to cause a tumor, but its still possible. Oddly, its possible that receiving someone elses stem cells (we call this allogeneic) might pose a lower cancer risk because your immune system is going to see those cells as foreign from the start.

But some stem cells, especially those with mutations, might be able to somewhat fly under the radar of the immune system to some extent even if they are from another person. This could allow them to grow into a tumor. The Pew report does a nice job of summarizing risks and there are several reports of tumors.

The possibility of infections after stem cell injections is another risk that is often discussed. Infections from injections of stem cells or other materials like PRP are probably the most common type of side effect. Bacteria can either sometimes already be in the product that is injected or can be introduced by poor injection or preparation methods by the one doing the procedure.

The distributor Liveyon had a product contaminated with bacteria that sickened at least a dozen people who were hospitalized. Some of them ended up in the ICU. A few may even have permanent issues.

Clinics using excellent procedures and products should have a low risk of infection more similar to getting any kind of invasive procedure even unrelated to stem cells.

Many preparations of stem cells sold at stem cell clinics these days are made from fat tissue or birth-related materials. I put stem cells in quotes because most fat and birth-related preparations only contain a small population of true stem cells.

In the case of adipose biologics, they mostly consist of a mixture of a dozen or so other kinds of cells found in fat.

The injections of fat cells are most often made IV right into the bloodstream. Fat cells just live in fat so they arent supposed to be floating around in your blood. As a result, after IV injection, many fat cells are thought to get killed right away.

Others end up landing in the lungs, where many are also probably meeting their doom. However, during this process of wiping out the fat cells it is possible that clots can start forming. Maybe the fat cells form small clots in the blood before they even get into the lungs. Either way, if the clots grow and are big enough, patients can get pulmonary emboli.

The same kind of risk may apply to IV injections or nebulizer inhalations of other kinds of stem cells.

There are other possible risks to stem cell injections too.

I wrote a post about possible graft versus host disease in stem cell recipients. This would only happen in people receiving someone elses stem cells. Its not clear if GvHD is something that happens to patients after going to clinics.

Beyond outright tumor formation it is also possible that stem cells will turn into an undesired or even dangerous tissue type. The example that comes to mind is the practice mentioned earlier of some clinics injecting fat cells into peoples eyeballs. What seems to have happened in some cases is that the mesenchymal cells (MSCs) that were injected turned into scar tissue, which caused retinal detachment. Unfortunately, what are called MSCs by some clinics can mostly consist of close relatives of fibroblasts or in some cases may even largely consist of fibroblasts. Fibroblasts are good at making scar tissue under some circumstances and that can create pull on surrounding tissues including the retina if inside the body.

Specific kinds of stem cells or routes of administration may pose unique risks as well. For instance, intranasal administration of stem cells is getting popular with unproven clinics and could lead to stem cells ending up in the brain.

Other products in the regenerative sphere that are not stem cells may be risky as well for various reasons. For instance, an exosome product harmed quite a few people in Nebraska.Some problems may relate to product contamination.

There have also been cases of unusual immune reactions to stem cell injections.

Finally, stem cells also pose unknown risks because of their power. We just dont have long-term follow up data to have a clear sense of risks.

Related Posts

Read the original:
Stem cell therapy side effects & risks: infections, tumors & more

Posted in Nebraska Stem Cells | Comments Off on Stem cell therapy side effects & risks: infections, tumors & more

HCG Online: Buy HCG Injection 1 Month Kit for Weight Loss

Posted: October 13, 2022 at 2:22 am

BUY 1 MONTH HCG INJECTIONS KIT INCLUDING ALL THE REQUIRED SUPPLIES

HCG is a protein-based hormone produced by the placenta during pregnancy.It is present at high levels during the early pregnancy. This hormone is in fact used in the hormone pregnancy tests. HCG hormone was first used as a weight loss remedy. It was noted by several physicians that women who are overweight lost weight when they got pregnant. Moreover, dozens of medical studies have shown that HCG hormone, when combined with a low-calorie diet and exercise increases can boost metabolism and helps lose a large amount of fats without feeling hungry. Human chorionic gonadotropin hormone is FDA approved for the treatments fertility issues but not as a weight loss tool. Only FDA drugs are allowed to use as an alternative drug. HCG is an Off-label Usage that common among medical professions. HCG is used in a very low dose for weight loss alongside a super-low-cal diet. The diet limits you to at 500 calories a day for 8 weeks while taking the hormone. You can get the hormone either by shot or by taking it as drops, pellets or sprays. The recommended daily injection for weight loss is somewhere between 125 iu to 175 iu. A good starting point is 150 iu but if you dont have much weight to lose, try starting at 125 iu and go from there. Human chorionic gonadotropin hormone is used in a much higher dose for fertility issues. A low dose of this hormone does not increase fertility. Some other benefits that you can get from using HCG include:

HCG Diet can offer you a safe and rapid weight loss.

The HCG diet focuses on losing weight and to maintain the weight through the combination of the HCG injections and the very low calorie diet. In the very low calorie diet, one has to maintain only 500 calories per day while having the daily injections of the Human chorionic gonadotropin hormone. This combination help resets the brains hypothalamus allowing ones body to use the abnormal fats and converts these fats into energy. The combination also ensures a long-term weight loss. It was Dr. A.T.W Simeons, a British endocrinologist, who developed the HCG diet. It aidshis obese patients in losing weight in order to avoid any deadly health conditions. His years of research and thousands of cases have led to the concept of the HCG Diet. Unlike other over-hyped and cosmetic diets of today, the HCG Diet is a healthier interpretation and implementation of losing weight. The HCG Diet focuses ones attention on eating smaller portions of foods that are low in fats, carbohydrates and calories. This promotes a more long-term weight loss. The HCG Diet is not solely a diet for the purpose of losing weight but its a diet that is meant to promote a healthier lifestyle by making a careful choice of using foods that are low in fats. There are several protocols and variations of the original version of the HCG Diet. However, all the different variations have common limitations when it comes to food consumption. Those who are on the HCG Diet should either limit or omit foods such as starches, sweet fruits, milk and eggs when on the protocol. The use of products that contain a fatty substance such as lotion, conditioner and make-ups should be omitted.

Mental Preparations: Losing weight can be a very difficult task if you are not mentally prepared. Without a full understanding as to why you are doing the diet, you wouldnt likely to succeed. Likewise, it would be very hard to stay committed and focused throughout the entire protocol if you will not set your goals. Physical Preparations:

The HCG Diet Protocol

The 40 Day Cycle

PHASE 1 Days 1- 2

Gorging Days with hCG Injections

The HCG diet Gorging days and why? Gorging days or commonly known as loading days is phase 1 of the HCG diet.It includes a two day stretch where you consume calorie dense foods to satisfaction. This phase is very important because this phase will set your hypothalamus gland in balance. But do not worry because whatever youve gained during the gorging days will be lost very quickly! Check this blog out to know more about the what and hows of the HCG diet Gorging days. You may also use our quick list of allowable foods on the HCG dieat when you shop and prepare for your meals.

Here is a sample meal plan on phase 2 of the HCG diet. For breakfast: Coffee or tea. Other option includes water with lemon juice sweetened with Stevia For lunch: 100 grams or 3.5 oz of protein serving, 100 grams of vegetable choice, one fruit and one Melba toast or a Grissini stick Snack: Fruit, low carb choice For dinner: 100 grams or 3.5 oz of protein serving, 100 grams of vegetable choice, one fruit and one Melba toast or a Grissini stick

The HCG diet Phase 2: Day 3-23 or 46 day The phase 2 of the HCG diet is the most challenging yet exciting part of the diet. This phase is also known as the very low calorie diet phase where you will only consume 500 calories a day. During this phase, your body will get used with using those stored abnormal fats as a source of energy. The foods are specific. You can only consume the approved HCG diet foods. No bread, sugars and fatty foods allowed.Apples, oranges, lemons strawberries and lime are just some of the most common fruit youll turn into when youre hungry. Your protein components will mostly be white fish and chicken. Vegetables like tomatoes, lettuce, and spinach will give you fibers and vitamins. You can also have beef for your protein choice as long as it is extra lean. The HCG diet Phase 3: The Maintenance Phase Just like the gorging days and phase 2 of the HCG diet, this phase is very vital. The main goal of this phase is for your body to maintain a metabolic balance with your new weight. Phase 3 of the HCG diet lasts for 3 weeks right after your last day of the very low calorie diet. During the Phase 3 of the HCG diet, you will increase your calorie intake to 1500 calories per day. You may now begin to eat any meats, fruits and vegetables. You can now consume milk, cheese and low sugar dairy products as long as they are healthy foods. However, you should avoid consuming a significant amount of starches like potatoes and corn. Exercise is encouraged at this phase. You may begin to do some regular workout routine of both aerobic and anaerobic exercises. Try doing light weight exercises with higher repetitions and at least 30 minutes of cardio a day. If you wish to do vigorous activities, you must consult first with your physician. You can start reintroducing back healthy oils into your body like extra virgin olive oil, coconut oil and flaxseed oil. Avoid using unhealthy oils like shortening and vegetable oils. You may also consume butter lightly.During this phase, you are allowed to use make-up, moisturizers and lotions. Once this phase is complete, you may start consuming back foods with sugar, starches and carbs but in moderation.We recommend oats, grains and wheat bread. Avoid heavy sugar and starches like potatoes, yams and rice. Avoid hydrogenated oils too which are usually found in pastries and canned goods. As much as possible stay away from processed foods and high fructose syrup such as those found in soda, fruit drinks and canned fruits. Continue to weigh yourself daily. During and after this phase you should not gain weight. You can at least gain about 2 pounds within Phase 3. However, once you will gain more than 2 pounds, observed a steak day the day youll notice a weight gain. Check this article about for the steak day. The HCG diet Phase 4 Phase 4 of the HCG diet is a lifetime maintenance program. Introduce starches back into your diet slowly and remember to keep sugar to a minimum. Continue consuming protein but stay away from fast foods and processed foods. Continue to weight yourself every day and if you have gained weight beyond your set baseline weight, use the steak day.

The rest of the skinny on the hCG diet HCG diet actually starts after the 2nd day of injecting the hormone. This is the phase where you will consume only 500 calories per day. The HCG diet history begins with Dr. A.T.W Simeons of Rome, Italy. He graduated at the University of Heidelberg and settled in Rome at the Salvatore Mundi International Hospital. Dr. Simeon is an author, a scientist and a researcher who developed the HCG Diet. His research on HCG hormone as weight loss component covered forty years of grappling with the central problem of being overweight. He investigated every theory, method and promising lead. Dr. Simeon carefully experiments and evaluated each theory. Upon his death in 1970 he stated: The protocol [the hCG diet] was everything that I hoped it would be no hunger, no food cravings, no grumpiness, no feeling of deprivation, no fatigue, a dramatic reshaping of the body with the burning of the secure problem area fat deposits. He then wrote his findings in his book Pounds and Inches. His book can give readers a thorough understanding of how the diet came to be and what HCG diet is all about. As Dr. Simeons writes in the Foreword of his book: This book discusses a new interpretation of the nature of obesity and while it does not advocate yet another fancy slimming diet it does describe a method of treatment which has grown out of theoretical considerations based on clinical observation. He came up with a conclusion that all cases of weight loss measures like using a laxative, dieting, exercises, appetite-reducing drugs, baths, massage are all temporary. None of the measures corrects the basic disorder. Through the HCG diet, the basic disorder is addressed, targeted and finally controlled. Fats are the enemy of everyone trying to lose weight. Fats are not just fats. There are actually three kinds of fats and the HCG diet deals with these three.

Abnormal fat is not available to the body duringa nutritional emergency like Normal Fat. The body cannot access abnormal fat easily that is why it is so difficult to lose this kind of fat even with exercise. When one goes on a diet by starving, they will lose their normal fat first. When this fat is exhausted, the body starts to burn the structural fat next. Then as a last resort, the body will yield the abnormal fat. When this happens, the dieter feels weak, tired, famished, haggard and hungry. But their hips, belly, thigh and upper arm only shows little improvement because they lose only the normal fat. The abnormal fat remains the same. Their skin becomes wrinkled and they look miserable. Dr. Simeons believed that this experience is one of the most depressing and frustrating experiences. Being overweight too has psychological effects. Those who are overweight can only feel physically well if they are not gaining any weight at all. They may, however, feel horrified by the appearances of their body when on a tight-fitting clothes or when they are nude. Being overweight is a vicious cycle. When you are overweight, you need more food to keep your body warm. But when you are just lean, you only need a small amount of food to keep your body at a certain temperature. That means to say if an overweight person eats only the foods that his body requires then hell be able to keep the weight stationary. However, this wasnt through at all. Many physicians have studied overweight patients under controlled conditions found out that overweight patients actually gain weight on a diet. At this, Dr. Simeons concluded that there was something missing. There must be some other mechanism at work. In an effort to unravel the mystery of the other condition, several studies have been conducted but were later abandoned. There were also a lot of theories regarding why someone is overweight but it was not the missing piece of the puzzle that Dr. Simeons was looking for. He then traveled to India. There he found doctors giving hCG to overweight patients with large hips, thigh and buttocks. He became curious and begin his first study of hCG.He observed that the Indian doctors were giving their patients small daily doses of the hormone. The result showed that their ravenous appetite disappeared and their hips also change. The abnormal fat deposit from their hips disappeared. Their body was slowly using the abnormal fats as fuel. For Dr. Simeons, HCG was the other mechanism. Its the secret to the diets success story. Medically defined, HCG or Human Chorionic Gonadotropin is a naturally occurring hormone produced in the placenta of pregnant women.Dr. Simeons found out that by restricting the diet to 500 calories combined with a small dose of hormone, patients can achieve the best results. In fact, patients can lose an average of 1 pound a day. They have reduced appetite and could go comfortably with their normal routines. It was also perfectly evident that only the abnormal fats were consumed. There were no signs of normal fat depletion. Their figures became entirely normal and their skin does not sag. Dr. Simeons also explained that women who are pregnant do not become obese. This is because their bodies are under the influence of an enormous amount of hormone that circulates around their bodies. Therefore, abnormal fat deposit does not form. Right after giving birth, the body becomes deprived of hCG and abnormal fats start to deposit. It was initially used to diagnose an early pregnancy by testing the urine. It has now been medically used for more than eighty years. It has no effects on normal sex glands of male and female. Its not a sex hormone. Pregnant women produce hormone for more than one million IUs (International unit) a day. On the HCG diet, dieters use only around 125 IU to 200 IU a day. This dosage does not change whether you weigh more or less than 150 pounds. Patients who weigh more or less than 150 pounds also follow the same very low calorie diet intake per day. Now the toughest and the most essential part to your success- the strict adherence to the 500 calorie diet. Here, only approved diet foods are allowed to eat. But whats good with this diet, you will NOT be hungry! The HCG hormone will reduce your food craving. The minimum HCG diet treatment is 26 days even if you need to lose just 5 pounds. Here, you will receive 23 injections followed by 3 days of diet but without injections. If you have more pounds to lose, you may continue the diet up to 43 days until you lose 34 pounds. You can do another cycle of 23 or 43 days but you need to rest for 6 weeks before you can start. Just follow the protocol exactly as instructed and you will be more than satisfied with the result.

The needle used in injecting the hormone is so small that it does not reach the muscle. It can only penetrate the skin and into the fats. There are several areas that you can inject yourself. These are:

Week 1 to 3 after the HCG Diet This is the maintenance phase. After completing the 23-day or the 43-day diet plan, you can eat all foods except sugars and starches because your body needs to adjust to your Abnormal Fat Loss. While on this phase, continue weighing yourself every morning. Week 4 to 6 after the Diet Continue with the maintenance phase but start introducing back sugar and starches. However, they should be in a small quantity only. Continue weighing yourself in the morning. 6 weeks after the Diet If you were not able to reach your weight loss goal after the 1st cycle of the HCG diet you can continue with the 2nd cycle. This is just the same with the 1st cycle. You can continue with another cycle until you reach your weight loss goal. Just make sure that you have your HCG diet break of 6 weeks in between each cycle.

Very Lean Beef (average of 52 calories) 93/7 Lean Ground Beef (3.5 oz) 150 calories Sirloin Tip Side Steaks (3.5 oz) 130 calories Bison (3 oz) 98 calories Cube Steak (3.5 oz) 160 calories Top Round Steak (3.5 oz) 166 calories Veal (avg 114 calories) Tri-Tip Steak (3.5 oz) 154 calories Veal, loin chop (3.5 oz) 117 calories Veal, sirloin (3.5 oz) 110 calories Seafoods (average of 98 calories) Cod (3.5 oz) 83 calories Flounder (3.5 oz) 90 calories Crab Meat (3.5 oz) 100 calories Haddock (3.5 oz) 88 calories Lobster (3.5 oz) 98 calories Halibut (3.5 oz) 110 calories Red Snapper (3.5 oz) 110 calories Tilapia (3.5 oz) 94 calories Shrimp (3.5 oz) 110 calories Chicken (average of 87 calories) Chicken Breast (3.5 oz) 87 calories Vegetables (average of 18.8 calories) Asparagus (3.5 oz) 20 calories Asparagus (2 tip) 1 calories Asparagus (small spear) 2 calories Asparagus (medium spear) 3 calories Asparagus (large spear) 4 calories Beet Greens (1 cup raw)-8 calories Broccoli- 34 calories Cauliflower- 22 calories Celery (3.5 oz) 15 calories Celery (medium stalk) 6 calories Cabbage (3.5 oz) 24 calories Cabbage (1 cup shredded) 17 calories Chard, Swiss raw (1 cup)-7 calories Chicory (1 head)- 9 calories Cucumber (3.5 oz) 12 calories Cucumber (small) 19 calories Cucumber (medium) 24 calories Cucumber (large) 34 calories Cucumber (English long) 60 calories Fennel (1 cup,sliced)- 27 calories Green beans (3/4 cup, cut)- 20 calories Green onions- 25 calories Green sweet pepper- 20 calories Lettuce, all varieties (3.5 oz) 10 cal. Lettuce, all varieties (1 cup) 8 cal. Lettuce, all varieties (small head) 32 calories Onions (medium yellow, raw)- 64 calories Red Radishes (3.5 oz) 12 calories Red Radishes (one medium) 1 cal. Spinach, raw (3.5 oz) 20 calories Spinach, raw (1 cup) 7 calories Spinach, frozen (3.5 oz) 23 calories Spinach, frozen (1 cup) 41 calories Spinach, cooked (3.5 oz) 31 calories Spinach, cooked (1 cup) 48 calories Tomato (3.5 oz) 20 calories Tomato (cherry) 3 calories Tomato (plumb) 11 calories Tomato (small) 16 calories Tomato (medium) 22 calories Tomato (large) 33 calories Fruit Apple (small) 55 calories Apple (medium) 72 calories Apple (large) 110 calories Blackberries (1 cup)- 62 calorie Blue Berries (1 cup)- 83 calories Grapefruit (1/2 cup)- 40 calories Lemon- 24 calories Lime- 20 calories Orange (navel) 69 calories Orange (Florida) 65 calories Orange (California) 59 calories Strawberries, 12 large 72 calories Strawberries, 20 medium 80 calories Pink Grapefruit (1/2 large) 53 calories Pink Grapefruit (1/2 med.) -41 calories Pink Grapefruit (Florida) 74 calories Bread Grissini Breadstick (3 g) 12 calories Melba Toast (3 gram) 12 calories Melba Toast (5 gram) 20 calories

Here is the original post:
HCG Online: Buy HCG Injection 1 Month Kit for Weight Loss

Posted in HCG Diet | Comments Off on HCG Online: Buy HCG Injection 1 Month Kit for Weight Loss

Allogene starts first pivotal trials of an ‘off-the-shelf’ cell therapy for cancer – BioPharma Dive

Posted: October 13, 2022 at 2:21 am

Allogene Therapeutics has begun the first pivotal test of an off-the-shelf cell therapy for cancer.

The biotechnology company, which has been at the forefront of a push in recent years to develop such treatments, known as allogeneic therapies and derived from donor cells, announced the start of two trials on Thursday. One will test a blood cancer drug known as ALLO-501A, while the other will evaluate a regimen Allogene uses to prepare patients for treatment. Assuming positive results, Allogene expects the studies will support approval applications for both of them.

The studies represent milestones for allogeneic cell therapies, which are meant to be more convenient alternatives to the personalized CAR-T treatments that have come to market for a handful of blood cancers. Allogene, spun out of Pfizers cell therapy work in 2018, is the largest and most advanced among the companies advancing them. Its run by former executives of Kite Pharma, which successfully developed the cell therapies now sold by Gilead Sciences.

Allogene raised more than a half a billion dollars in private financing and an initial public offering to fund its work. The company has had a bumpy ride since then, however. Its cell therapies, including ALLO-501A, have shown promise, but also face lingering questions about their durability and effectiveness compared to CAR-T treatments. The field has also gotten more competitive, with an emerging group of companies advancing therapies using different types of cells and CAR-T moving into earlier lines of care.

Additionally, Allogenes research was delayed by the unexpected finding of a chromosomal abnormality in a treated patient. The companys treatment was exonerated, but the FDA froze Allogenes programs for months during the investigation. Longtime partner Servier cut ties with the company last month as well.

The company now has the chance to prove how its technology stacks up. ALLO-501A is being tested in a Phase 2 study in patients with relapsed or refractory large B cell lymphoma, a setting for which multiple CAR-T treatments are already available.

In a research note, RBC Capital Markets analyst Luca Issi noted that its trial, ALPHA2, mimics the design of the studies underlying approvals of those treatments for lymphoma. Its a single-arm study of about 100 patients whove previously received at least two prior treatments, but not a CAR-T therapy. The study will be judged by ALLO-501As ability to induce a response. Allogene didnt disclose a bar for success, but Issi, after speaking with management, said executives believe efficacy needs to be in the range of approved CAR-T therapies.

Notably, the company is testing a single dose of the treatment, not a repeat-dosing regimen Allogene has been experimenting with to strengthen the effects of ALLO-501A. Issi indicated the decision was made for ease and convenience.

Allogenes other study, EXPAND, is a registrational trial for ALLO-647, an antibody drug the company is using to prepare patients for treatment. That study will enroll about 70 patients and have a control arm that doesnt receive Allogenes drug. Updates are expected by the end of the year, Allogene said.

Allogene shares climbed 12% in pre-market trading Friday, though at about $11, shares still trade well below their highs of about $54 apiece in 2020.

Read the original post:
Allogene starts first pivotal trials of an 'off-the-shelf' cell therapy for cancer - BioPharma Dive

Posted in Cell Therapy | Comments Off on Allogene starts first pivotal trials of an ‘off-the-shelf’ cell therapy for cancer – BioPharma Dive

Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers – Business Wire

Posted: October 13, 2022 at 2:21 am

BALTIMORE--(BUSINESS WIRE)--Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and cancers, today announced the completion of a $31 million Series B financing. The fundraise was led by Cambrian BioPharma and new investor Solve FSHD. New investors included Riptide Ventures and Cedars Sinai, which participated alongside TEDCO and other existing investors. Proceeds from the financing will be used to advance Vitas lead pre-clinical program VTA-100 for limb-girdle muscular dystrophy (LGMD2A) to the clinic. It will also fund the development of Vitas newest program, VTA-120 for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD), and to further expand Vitas discovery pipeline. Since inception, Vita has raised a total of $66 million.

The support from this strategic group of quality investors further validates Vitas cell therapy platform and our mission to bring transformative therapies that target the root cause of disease to patients with muscle disorders and cancers, said Douglas Falk, MS, Chief Executive Officer at Vita Therapeutics. This syndicates confidence in our ability to further progress our programs is energizing and we are thrilled to have them as partners. We are making notable progress with our investigational IND-enabling studies for VTA-100 and are on track to reach the clinic with this important therapeutic candidate within 18 months. Additionally, we are excited to further expand our pipeline to include VTA-120 for the treatment of patients with FSHD. Im incredibly proud of our entire team and the steady momentum we continue to have.

Chip Wilson, Founder of lululemon athletica and of Solve FSHD noted, Living with FSHD for over 30 years, my upper body muscles are quite wasted. We are hopeful that Vitas cell therapy approach will stimulate muscle regeneration and help people like me to build up muscle faster than it breaks down.

Currently there are no treatments available for FSHD, and there is an urgent need to develop disease-modifying treatments that not only regenerate muscle but correct the genetic defect that otherwise leads to the muscles inability to repair itself, added Eva Chin, Executive Director for Solve FSHD. We are pleased to support Vita as they continue to expand their induced pluripotent stem cell (iPSC) technology towards FSHD and LGMD.

Vita Therapeutics aligns with Cambrians mission of building medicines that will redefine healthcare in the 21st century, said Cambrian BioPharma Chief Executive Officer, James Peyer, PhD. The team, as well as the scientific platform, continues to impress us as they aim to solve for treatments that go beyond symptom management to truly impact these diseases in a positive way.

Pipeline Overview

Vita Therapeutics current pipeline includes lead program, VTA-100 for the treatment of LGMD2A, VTA-120 for the treatment of FSHD, and VTA-300 targeting multiple cancers.

About Limb-Girdle Muscular Dystrophy

Limb-girdle muscular dystrophy (LGMD) is a group of disorders that cause weakness and wasting of muscles closest to the body (proximal muscles), specifically the muscles of the shoulders, upper arms, pelvic area, and thighs. The severity, age of onset, and disease progression of LGMD vary among the more than 30 known sub-types of this condition and may be inconsistent even within the same sub-type. As the atrophy and muscle weakness progresses, individuals with LGMD begin to have trouble lifting objects, walking, and climbing stairs, often requiring the use of assistive mobility devices. There is currently no cure for LGMD, with treatments limited to supportive therapies such as corticosteroids.

About Facioscapulohumeral Muscular Dystrophy

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscular dystrophy, although thirty percent of new FSHD patients have no prior family history of the disease and result from a congenital spontaneous genetic mutation. FSHD typically first presents with weakness of the muscles of the facial muscles and scapular region, with proximal weakness of the pectoral and abductor muscles limiting upper extremity function at the shoulder girdle. Onset is typically in the teenage and early adult years, but it can present in infancy, which tends to be a more aggressive course. The disease is slowly progressive and approximately 20% of patients are wheelchair bound by age 50. Currently there are no treatments specifically indicated for use in FSHD, with no disease-modifying treatments available.

About Vita Therapeutics

Vita Therapeutics is a biotechnology company developing state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers. Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. The Company is progressing its lead program VTA-100 for the treatment of limb-girdle muscular dystrophy (LGMD2A) with the goal of filing Investigational New Drug Applications with the US Food and Drug Administration in the next 18 months. Long term, the Company is developing its pipeline of cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics is currently working with numerous partners, including PanCella, Wyss Institute, and Johns Hopkins University, to advance their clinical programs. Learn more about the company at http://www.Vitatx.com.

About Cambrian BioPharma

Cambrian BioPharma is building the medicines that will redefine healthcare in the 21st century therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company, Cambrian is advancing multiple scientific breakthroughs each targeting a biological driver of aging. Its approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life during aging. For more information, please visit http://www.cambrianbio.com or follow us on Twitter @CambrianBio and LinkedIn.

About SOLVE FSHD

SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist Chip Wilson, the founder of technical apparel company lululemon athletica inc. Chip has committed $100 million to kick-start funding into projects that support the organizations mission to find a cure for FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD. For more information, please visit: http://www.solvefshd.com.

Visit link:
Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers - Business Wire

Posted in Cell Therapy | Comments Off on Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers – Business Wire

CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study – GlobeNewswire

Posted: October 13, 2022 at 2:21 am

Wilmington, Delaware, United States, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. The solutions in the global CAR T-cell therapy market are increasingly being hailed as cutting-edge innovations in the field of cancer treatments. Clinical trials conducted by players in the global CAR T-cell therapy market are displaying promising results, particularly in end stage patients suffering from acute lymphocytic leukemia. The success of these trials is translating into substantial revenue grab opportunities for market players. As per a recent professional survey report, the global CAR T-cell therapy market is estimated to grow at a CAGR of 30.6% over the forecast period of 2021 to 2031.

Players in the global CAR T-cell therapy market are working closely with research institutes and hospitals to develop cost-effective solutions, as the high cost of CAR T-cell therapies remains a major barrier for the adoption of these solutions. Chimeric Antigen Receptors or CAR are protein constructs that have been genetically engineered to be incorporated into patients cytotoxic T cells for aiding them in fighting cancer cells by efficiently recognizing them. Players in the global CAR T-cell therapy market offer various types of novel products, including tisagenlecleucel, lisocabtagene maraleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, and idecabtagene vicleucel, among others.

Get Exclusive PDF Sample Copy of CAR T-cell Therapy Market https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83242

CAR T-cell Therapy Market Key Findings of the Report

CAR T-cell Therapy Market Growth Drivers

Ask for References https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=83242

CAR T-cell Therapy Market Key Players

Some of the key companies operating in the global CAR T-cell therapy market include Novartis AG, Amgen, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Bristol-Myers Squibb, Sorrento Therapeutics, Inc., Gilead Sciences, Inc., and bluebird bio, Inc., among others. Some of the noteworthy expansion strategies employed by these players include acquisitions, strategic alliances, geographical expansion, new product launches, and distribution agreements.

Furthermore, leading players in the global CAR T-cell therapy market are also focusing on research and development to design and develop new types of CAR T-cell therapy products intended for treating different types of cancer. Stakeholders in the global CAR T-cell therapy market are complying with various research and health policy frameworks in order to adhere to stringent regulations put forth by governments across the world.

CAR T-cell Therapy Market Regional Growth Assessment

In 2020, North America region held the dominant share of the global CAR T-cell therapy market. This leading industry positioning of the North America region can be attributed to the presence of a large number of leading international players, rising healthcare spending, and early adoption of new medical technologies and techniques. Furthermore, rising number of research activities in the region is also boosting growth within the North America CAR T-cell therapy market. In coming years, Asia Pacific is also expected to witness significant growth in the global market.

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=83242

CAR T-cell Therapy Market: Segmentation

CAR T-cell Therapy Market, by Product Type

CAR T-cell Therapy Market, by Indication

CAR T-cell Therapy Market, by End User

CAR T-cell Therapy Market, by Region

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research:

Ophthalmic Drugs Market: The ophthalmic drugs market is expected to reach US$ 50.2 Bn by the end of 2031 at a CAGR of 6.83% from 2022 to 2031.

Homeopathic Products Market: The global homeopathic products market is anticipated to reach more than US$ 32.4 Bn by the end of 2031 at a CAGR of 11.6% from 2022 to 2031.

Pain Management Therapeutics Market: The global pain management therapeutics market is anticipated to reach more than US$ 98.0 Bn by the end of 2031 at a CAGR of 2.9% from 2022 to 2031.

Peptide Therapeutics Market: The global peptide therapeutics market is anticipated to reach more than US$ 91.25 Bn by 2031 at a CAGR of 8.8% from 2022 to 2031.

Collagen Peptide & Gelatin Market: The global collagen peptide and gelatin market is anticipated to reach more than US$ 7.8 Bn by the end of 2031 at a CAGR of 5.0% from 2022 to 2031.

Premenstrual Syndrome Treatment Market: The global premenstrual syndrome treatment market is anticipated to reach more than US$ 1.9 Bn by the end of 2031 at a CAGR of 3.4% from 2022 to 2031.

Synthetic Biology Market: The global synthetic biology market is anticipated to reach more than US$ 74.7 Bn by the end of 2031 at a CAGR of 21.3% from 2022 to 2031.

Closed System Transfer Devices [CSTD] Market: The global closed system transfer devices (CSTD) market is expected to expand at a CAGR of ~11% from 2020-2030.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyse information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:sales@transparencymarketresearch.com

Link:
CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study - GlobeNewswire

Posted in Cell Therapy | Comments Off on CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study – GlobeNewswire

Page 169«..1020..168169170171..180190..»